Switch theme
Sign up to access all valuation multiples
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
2007
167
LTM Revenue $155M
LTM EBITDA n/a
$407M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akebia Therapeutics has a last 12-month revenue of $155M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Akebia Therapeutics achieved revenue of $195M and an EBITDA of -$8.3M.
Akebia Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akebia Therapeutics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $293M | $195M | $151M | $155M | XXX |
| Gross Profit | $60.2M | $208M | $120M | XXX | XXX |
| Gross Margin | 21% | 107% | 80% | XXX | XXX |
| EBITDA | -$25.5M | -$8.3M | n/a | n/a | XXX |
| EBITDA Margin | -9% | -4% | NaN% | 0% | XXX |
| Net Profit | -$283M | -$92.6M | -$51.9M | XXX | XXX |
| Net Margin | -97% | -48% | -34% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Akebia Therapeutics's stock price is $2.
Akebia Therapeutics has current market cap of $393M, and EV of $407M.
See Akebia Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $407M | $393M | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Akebia Therapeutics has market cap of $393M and EV of $407M.
Akebia Therapeutics's trades at 2.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Akebia Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Akebia Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $407M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -6.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAkebia Therapeutics's NTM/LTM revenue growth is 22%
Akebia Therapeutics's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Akebia Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Akebia Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Akebia Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -22% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 32% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 86% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akebia Therapeutics acquired XXX companies to date.
Last acquisition by Akebia Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Akebia Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Akebia Therapeutics founded? | Akebia Therapeutics was founded in 2007. |
| Where is Akebia Therapeutics headquartered? | Akebia Therapeutics is headquartered in United States of America. |
| How many employees does Akebia Therapeutics have? | As of today, Akebia Therapeutics has 167 employees. |
| Who is the CEO of Akebia Therapeutics? | Akebia Therapeutics's CEO is Mr. John P. Butler. |
| Is Akebia Therapeutics publicy listed? | Yes, Akebia Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Akebia Therapeutics? | Akebia Therapeutics trades under AKBA ticker. |
| When did Akebia Therapeutics go public? | Akebia Therapeutics went public in 2014. |
| Who are competitors of Akebia Therapeutics? | Similar companies to Akebia Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Akebia Therapeutics? | Akebia Therapeutics's current market cap is $393M |
| What is the current revenue of Akebia Therapeutics? | Akebia Therapeutics's last 12-month revenue is $155M. |
| What is the current EV/Revenue multiple of Akebia Therapeutics? | Current revenue multiple of Akebia Therapeutics is 2.6x. |
| What is the current revenue growth of Akebia Therapeutics? | Akebia Therapeutics revenue growth between 2023 and 2024 was -22%. |
| Is Akebia Therapeutics profitable? | Yes, Akebia Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
